Can You Take Levothyroxine and Liothyronine at the Same Time?

Levothyroxine (a synthetic form of the T4 thyroid hormone) and liothyronine (a synthetic form of T3) can be taken together, and many people do so under medical supervision. This approach, called combination therapy, has been studied in clinical trials for over two decades. Most endocrinology guidelines still recommend levothyroxine alone as the standard first-line treatment, but they leave the door open for adding liothyronine in specific situations. The real questions are when it makes sense, who it helps, and what the trade-offs look like.

Why Someone Would Consider Adding T3

Your thyroid gland naturally produces both T4 and T3. When it fails and you take levothyroxine, you’re getting only T4, which your body then converts into the more active T3 through enzymes called deiodinases in tissues like the liver, kidneys, and brain.¹ For many people, this conversion works well enough. But a substantial number of patients on levothyroxine report lingering symptoms even when their blood tests look normal.

In a UK study, about 40% of patients treated with levothyroxine still had hypothyroid symptoms, compared with roughly 25% of a control population.² A separate study found that about 64% of levothyroxine-treated patients scored above the average symptom burden of controls, versus 44% in the control group, with dry skin, fatigue, cold intolerance, and memory problems all significantly more common in the treated group.³ Other research puts the proportion of patients reporting at least one residual symptom as high as 76%, with dry skin and weight gain being the most frequent complaints.⁴

These are not small numbers. The frustration patients feel is real and widespread, and it drives interest in combination therapy as something that might close the gap levothyroxine alone leaves open.

What the Clinical Trials Actually Show

Here is where the picture gets complicated, and honestly a little unsatisfying. Dozens of trials have compared combination therapy against levothyroxine alone, and the aggregate results are mixed. A review of 17 studies found that 10 showed no consistent advantage for either approach, four showed improvements in quality of life, mood, or thinking with combination therapy, and two noted that patients subjectively preferred the combination even when objective measures didn’t clearly differ.⁵

A 2024 meta-analysis found that combination therapy produced lower scores on a general psychological distress questionnaire compared with levothyroxine alone, meaning patients reported feeling somewhat better mentally. Total T3 levels were also significantly higher with combination therapy, which is expected since you’re directly supplying T3. But there was no significant difference in heart rate, cholesterol levels, TSH, or a widely used thyroid-specific quality-of-life score.⁶ Another systematic review found a small but statistically significant benefit in symptom scale scores for combination therapy, but no significant improvement in overall quality of life.⁷

So the evidence points toward a modest benefit in some symptom measures, but nothing dramatic when you look at averages across whole study populations. The challenge is that averaging may be hiding a real effect in a subgroup of people who genuinely respond well, while the majority don’t change much.

Patients Tend to Prefer Combination Therapy

One of the more striking findings across trials is that patients consistently prefer combination therapy when given the option, even in studies where objective outcomes like blood work don’t clearly differ. A meta-analysis of preference data found that about 52% of patients preferred levothyroxine plus liothyronine (or desiccated thyroid), while only 24% preferred levothyroxine alone, and 24% had no preference. The pooled relative risk of preferring combination therapy over monotherapy was roughly double.⁸

This gap between “studies don’t show dramatic objective differences” and “patients clearly like it better” is one of the central tensions in this field. It might reflect unmeasured benefits that standard outcome tools miss, a placebo effect from trying something new, or genuinely improved well-being that doesn’t map neatly onto questionnaire scores designed for research. Researchers have been arguing about this for years, and the patient preference data is hard to dismiss.

Genetics May Determine Who Benefits

One promising explanation for why some people feel better on combination therapy and others don’t involves genetic variation in the enzymes that convert T4 to T3. A variant in the DIO2 gene (known as Thr92Ala) is carried by a meaningful portion of the population. People with two copies of this variant showed worse psychological well-being scores on levothyroxine alone, and they experienced greater improvement when switched to combination therapy, by about 2.3 points on a general health questionnaire at three months.⁹ The variant didn’t change thyroid hormone levels in the blood, suggesting it affects conversion at the tissue level, where it matters most for symptoms but is invisible on a standard blood test.

A separate trial looked at combining DIO2 variants with a variant in another gene called MCT10, which helps transport thyroid hormones into cells. Among patients carrying both variants, 100% preferred combination therapy. Among those carrying one variant, 63% preferred it. Among those with neither, 42% preferred it.¹⁰ That is a remarkably clean dose-response pattern. It suggests that impaired T4-to-T3 conversion is a real biological mechanism behind residual symptoms in at least some patients, and that giving T3 directly bypasses the bottleneck.¹¹

Genetic testing for deiodinase variants isn’t routine yet, but these findings help explain why the overall trial data look lukewarm while a subset of patients report transformative improvement. If you’re averaging together people who biologically need extra T3 with people who convert T4 just fine, the group result will always be underwhelming.

The Pharmacokinetic Problem With Liothyronine

One practical challenge with combining these medications is that liothyronine behaves very differently in the body than levothyroxine. Levothyroxine has a long half-life and produces stable blood levels throughout the day. Liothyronine, by contrast, peaks quickly and then declines. In one study, a single dose of liothyronine hit peak blood levels at about 2.5 hours, with the concentration roughly tripling baseline values.¹² Another study documented significant swings in T3 levels with once-daily liothyronine dosing, with peak concentrations averaging around 293 ng/dL.¹³

These peaks can push T3 into a temporarily elevated range, which some patients feel as heart palpitations, anxiety, or a jittery sensation before the level drops back down. This is one reason many clinicians who prescribe combination therapy split the liothyronine dose into two daily doses, or recommend taking it at separate times of day. The spikes also make blood test interpretation tricky: if you draw blood two hours after taking liothyronine, your T3 will look very different than if you draw it eight hours later.

What Guidelines Say

Major endocrinology bodies take a cautious position. The European Thyroid Association’s guidelines state that levothyroxine alone should remain the standard treatment, but they acknowledge that adding liothyronine can be considered as an “experimental approach” in patients who have persistent complaints despite normal TSH levels, provided other explanations like coexisting autoimmune conditions have been ruled out.¹⁴ The American Thyroid Association’s guidelines take a similar tone. In practice, this means that combination therapy is not first-line, but it is not off-limits either.

The recommended approach when trying combination therapy is typically to reduce the levothyroxine dose somewhat and add a small amount of liothyronine, aiming for a T4-to-T3 ratio in the range of about 13:1 to 20:1 by weight. This roughly mimics the ratio the healthy thyroid gland produces. The guidelines are clear that TSH should be monitored carefully and kept within the normal range to avoid overtreatment.

Safety and Side Effects

The safety concern most often raised is that the T3 peaks from liothyronine could cause symptoms resembling an overactive thyroid, especially heart-related problems. A 2024 review of safety data from randomized trials found that combination therapy did not raise clear or consistent safety issues, even in studies that used T4-to-T3 ratios lower than what current experts recommend. Spontaneous reports of side effects from a commercial combination product also showed a low overall rate, including for symptoms suggestive of thyroid hormone excess.⁶ That said, the trials have mostly been relatively short (weeks to months), so the long-term cardiovascular effects remain an open question.

One area worth watching is bone health. Excess thyroid hormone is known to accelerate bone loss, and one study found that patients treated with levothyroxine for at least two years had lower bone density at the lumbar spine compared with untreated groups, an effect linked to TSH suppression.¹⁵ The concern with combination therapy is that transient T3 peaks could add to this risk. In practice, keeping TSH within the normal range is the main safeguard, since a suppressed TSH is the clearest signal of overtreatment regardless of which formulation you take.

How to Take Them Together

If you and your doctor decide to try combination therapy, the medications are usually taken in the morning on an empty stomach, the same way you’d take levothyroxine alone. Both hormones are absorbed in the small intestine, and the same substances that interfere with levothyroxine absorption interfere with liothyronine. Calcium and iron supplements, for instance, can bind thyroid hormones in the gut and reduce how much gets into your bloodstream.¹⁶ The standard advice of waiting 30 to 60 minutes before eating, and separating thyroid medication from calcium or iron by at least four hours, applies to both hormones.

Some patients split the liothyronine dose, taking part in the morning and part in the early afternoon, to reduce the peak-and-trough effect. This adds complexity to an already finicky medication routine, and there’s no consensus on whether it meaningfully improves outcomes over a single morning dose. Still, it’s a common practical approach among clinicians experienced with combination therapy.

Combination Therapy Versus Desiccated Thyroid

Desiccated thyroid extract, derived from pig thyroid glands, is another way to get both T4 and T3. It naturally contains both hormones, but in a fixed ratio of roughly 4:1 by weight, which delivers a substantially higher proportion of T3 than synthetic combination therapy typically uses. A trial comparing desiccated thyroid, synthetic combination therapy, and levothyroxine alone found no significant differences among the three groups on a thyroid symptom questionnaire or any secondary outcome measures.¹⁷ This is worth knowing because some patients drawn to combination therapy end up exploring desiccated thyroid as an alternative. The advantage of synthetic combination therapy is that the T4 and T3 doses can be adjusted independently, while desiccated thyroid locks you into a fixed ratio.

The Cost and Access Problem

In many countries, liothyronine has become expensive. In England and Wales, the cost per patient per year for liothyronine rose from about £550 to £3,000 around 2015-2016, and despite some decline since then, it remained around £2,500 as of 2020.¹⁸ This dramatic price increase led some healthcare systems to restrict prescribing, meaning patients who might benefit from combination therapy couldn’t access it. In the US, liothyronine is available as a generic and tends to be less expensive than in the UK, but insurance coverage varies. The cost disparity between levothyroxine (which costs pennies per day) and liothyronine is a real barrier for many patients worldwide.

Slow-Release T3 Formulations in Development

The pharmacokinetic spike-and-drop pattern of current liothyronine tablets is widely recognized as the biggest obstacle to better combination therapy. If T3 could be delivered in a steady trickle rather than a flood, it would more closely mimic what a healthy thyroid does naturally. Several groups are working on this problem.

One approach under active study is a metal-coordinated form of T3 called poly-zinc-liothyronine. In animal studies, this formulation produced a T3 peak about 30% lower than standard liothyronine, delayed the peak from roughly 3.5 hours to 9 hours, and extended the period of relatively stable T3 levels from about 5 hours to nearly 8 hours.¹⁹ Other formulations use matrix tablets designed to release T3 over a full 24-hour period, and at least one randomized controlled trial is underway testing a sustained-release liothyronine tablet in combination with levothyroxine.²⁰ Researchers are also exploring more speculative approaches, including nanoparticle delivery systems and T3-containing subcutaneous implants.²¹

None of these are commercially available yet, but they represent a meaningful shift in the field. If a sustained-release T3 product reaches the market, it could fundamentally change the combination therapy debate by removing the main pharmacological objection to adding T3. The current trials should provide clearer data within the next few years on whether smoother T3 delivery translates into better patient outcomes compared with what the existing immediate-release liothyronine tablets can achieve.